Stock Events

Stock Events

Serina Therapeutics 

0
41
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q1 2026
Q2 2026
Next
-0.5
-0.43
-0.36
-0.29
Expected EPS
-0.292468
Actual EPS
N/A

Financials

-15,113.29%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
110,290.7Revenue
-16.67MNet Income

Analyst Ratings

6.07Average Price Target
The highest estimate is 6.07.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2BO.STU. It's not an investment recommendation.
Microsoft
5
MSFT
NVIDIA
5
NVDA
Coca-Cola
5
KO
Apple
4
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that could directly compete with AgeX's regenerative medicine and cellular therapy approaches.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing space, making it a direct competitor in developing therapies that could overlap with AgeX's focus on age-related diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing in the same space as AgeX by targeting genetic diseases and conditions.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, potentially competing with AgeX in the market for therapies targeting age-related diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with AgeX in the field of molecular biology and therapy development for various conditions.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics is advancing the field of CRISPR-based genetic and cellular therapies, which could compete with AgeX's therapeutic approaches.
Voyager Therapeutics
VYGR
Mkt Cap218.13M
Voyager Therapeutics focuses on the development of gene therapies for neurodegenerative diseases, potentially competing with AgeX's focus on age-related conditions.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is working on programmed cellular immunotherapies for cancer and immune disorders, which could compete with AgeX's approach to regenerative medicine and cellular therapies.

About

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Show more...
CEO
Steven A. Ledger
Employees
16
Country
United States
ISIN
US81751A1088
WKN
000A407UV

Listings

XASE
US
SER
MU
DE
0X4.MU
STU
DE
2BO.STU
F
DE
2BO.F

0 Comments

Share your thoughts

FAQ

What is Serina Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Serina Therapeutics stocks are traded under the ticker 2BO.STU.
When is the next Serina Therapeutics earnings date?▼
Serina Therapeutics is going to release the next earnings report on November 18, 2026.
What were Serina Therapeutics earnings last quarter?▼
2BO.STU earnings for the last quarter are -0.48 EUR per share, whereas the estimation was -0.4 EUR resulting in a -17.95% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Serina Therapeutics revenue for the last year?▼
Serina Therapeutics revenue for the last year amounts to 110,290.7 EUR.
What is Serina Therapeutics net income for the last year?▼
2BO.STU net income for the last year is -16.67M EUR.
How many employees does Serina Therapeutics have?▼
As of September 04, 2026, the company has 16 employees.
In which sector is Serina Therapeutics located?▼
Serina Therapeutics operates in the Health & Wellness sector.
When did Serina Therapeutics complete a stock split?▼
Serina Therapeutics has not had any recent stock splits.
Where is Serina Therapeutics headquartered?▼
Serina Therapeutics is headquartered in HUNTSVILLE, United States.